

**Diaceutics grows its lab network and data capabilities in Europe**

*New data will deliver enhanced insights to Diaceutics' customers and drive new sales opportunities across multiple geographies*

**Belfast and London, 27 February 2024 - Diaceutics PLC (AIM: DXRX)**, a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce it has expanded its data supply network which will significantly increase the number of labs through which Diaceutics is sourcing data in Europe and will broaden the Company's European data coverage. This data will accelerate the rollout of the DxRx Signal product in key EU markets of Germany, France, Italy, Spain and the United Kingdom (DxRx Signal has only previously been offered by Diaceutics in the US market).

The increased data is now available to Diaceutics customers enabling them to find more patients eligible for their new and innovative therapies.

**Jordan Clark, Chief Data Officer of Diaceutics commented:** *"This data will further endorse our position as a leading provider of data to biotech and pharma companies as they commercialize their products, find and deliver therapies to patients across multiple geographies."*

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer.

**Enquiries:**

**Diaceutics PLC**

Tel: +44 (0)28 9040 6500

Ryan Keeling, Chief Executive Officer  
Nick Roberts, Chief Financial Officer  
Jordan Clark, Chief Data Officer

investorrelations@diaceutics.com

**Stifel Nicolaus Europe Limited (Nomad & Broker)**

Tel: +44 (0)20 7710 7600

Ben Maddison  
Nick Harland  
Kate Hanshaw

**Alma Strategic Communications**

Tel: +44 (0)20 3405 0205

Caroline Forde  
Kinvara Verdon

diaceutics@almastrategic.com

**About Diaceutics**

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network<sup>®</sup>.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCDXGDDDBDDGSL